Charité - University Hospital Berlin
Augustenburger Platz 1
Beate Rau has specialized in surgical oncology, especially in upper and lower GI-tract- and thoracic-cancer-surgery. Her main interest is surgical oncology, what she mostly did the last 30 years.
Hyperthermia is one of her topics. With different technology (phased array technology, thermotherapy induced by nanoparticles, and others) she was very much involved in research and generating multimodal treatment concepts. Convinced by hyperthermia she achieved experience in cytoreductive surgery (CRS) for peritoneal surface malignancies (PSM) and HIPEC over the last 15 years. With her effort, she got the status of a centre of excellence and reference for surgical treatment of PSM in Germany, announced by the German society of general surgery (DGAV) and is therefore responsible for one of the few centres in Germany.
She is committed to the German Surgical Society of Oncology and engaged with the PSM Group, which is called PSOGI. For the topic, she organises annually repeating courses to educate skills and knowledge to participants in the field of PSM.
She started her academic carrier in Heidelberg Rohrbach, University of Heidelberg and at the Charité in Berlin. She is very much involved in education of the students and young trainees. She is board member of the European Society of Surgical Oncology (ESSO). Since 2015 she is the head of the Section Special Surgical Oncology at the Charité.
Senior Consultant Surgeon – Head of the Section Special Surgical Oncology
Campus Charité Mitte | Campus Virchow-Klinikum
Chair: Univ.-Prof. Dr. med. J. Pratschke
- The efficacy of treatment options for patients with gastric cancer and peritoneal metastasis. Rau B, Brandl A, Thuss-Patience P, Bergner F, Raue W, Arnold A, Horst D, Pratschke J, Biebl M. Gastric Cancer. 2019 May 7. doi: 10.1007/s10120-019-00969-1. [Epub ahead of print]
- PIPAC-OV3: A multicenter, open-label, randomized, two-arm phase III trial of the effect on progression-free survival of cisplatin and doxorubicin as Pressurized Intra-Peritoneal Aerosol Chemotherapy (PIPAC) vs. chemotherapy alone in patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. Bakrin N, Tempfer C, Scambia G, De Simone M, Gabriel B, Grischke EM, Rau B. Pleura Peritoneum. 2018 Sep 25;3(3):20180114. doi: 10.1515/pp-2018-0114. eCollection 2018 Sep 1.
- Pressurized intraperitoneal aerosol chemotherapy and its effect on gastric-cancer-derived peritoneal metastases: an overview. Alberto M, Brandl A, Garg PK, Gül-Klein S, Dahlmann M, Stein U, Rau B.Clin Exp Metastasis. 2019 Feb;36(1):1-14. doi: 10.1007/s10585-019-09955-4. Epub 2019 Feb 4. Review.
- Perioperative Systemic Chemotherapy, Cytoreductive Surgery, and Hyperthermic Intraperitoneal Chemotherapy in Patients With Colorectal Peritoneal Metastasis: Results of the Prospective Multicenter Phase 2 COMBATAC Trial. Glockzin G, Zeman F, Croner RS, Königsrainer A, Pelz J, Ströhlein MA, Rau B, Arnold D, Koller M, Schlitt HJ, Piso P. Clin Colorectal Cancer. 2018 Dec;17(4):285-296. doi: 10.1016/j.clcc.2018.07.011. Epub 2018 Jul 31.
- Cytoreductive surgery and HIPEC improve survival compared to palliative chemotherapy for biliary carcinoma with peritoneal metastasis: A multi-institutional cohort from PSOGI and BIG RENAPE groups. Amblard I, Mercier F, Bartlett DL, Ahrendt SA, Lee KW, Zeh HJ, Levine EA, Baratti D, Deraco M, Piso P, Morris DL, Rau B, Tentes AAK, Tuech JJ, Quenet F, Akaishi E, Pocard M, Yonemura Y, Lorimier G, Delroeux D, Villeneuve L, Glehen O, Passot G; PSOGI and BIG RENAPE working groups. Eur J Surg Oncol. 2018 Sep;44(9):1378-1383. doi: 10.1016/j.ejso.2018.04.023. Epub 2018 Jun 19.